トリペプチド-10-シトルリンとアセチルヘキサペプチド-3の組み合わせの有効性研究

BACKGROUND: Bioactive peptides have beneficial effects on the skin. 目的：アセチルヘキサペプチド-3およびトリペプチド-10シトルリンの効果と、これら2つのペプチド間の相乗効果の可能性を評価するために調査しました。 方法：24人の健康なボランティアを無作為化して、アセチルヘキサペプチド-3とトリペプチド-10シトルリン（グループG1）、トリペプチド-10シトルリン（群、G2）、アセチルヘキサペプチド-3（グループG3）、またはペプチド（Group G4) for 60 days.評価された皮膚の特性には、皮膚ビシオスカンとテワメーターを使用した皮膚微小トップグラフィー、パラメーターCR2およびCR3、およびそれぞれそれぞれ皮膚下皮膚水損失（TEWL）が含まれていました。 結果：20日後、G1とG2グループの間の測定（Cr2 P = .045、Cr3 P = .044）、G2およびG3グループ（Cr2 P = .017、Cr3 P = .017）、G3およびG4グループ（G3およびG4グループ）CR2 P=.022), and G2 and G4 groups (cR3 P=.028) from baseline were significant.60日後、グループG1とG3（Cr2 P = .016、Cr3 P = .025）、グループG2およびG3（Cr2 P = .044、Cr3 = P = .044）、およびグループG1およびG4（Cr2（Cr2）間の測定値P=.025) were significant.After 20 days, changes in TEWL between groups G1 and G3 (P=.03), groups G2 and G3 (P=.045), and groups G3 and G4 (P=.025) were significant.After 40 days, changes between groups G2 and G3 (P=.028) and groups G3 and G4 (P=.01) from baseline were significant. CONCLUSION: Our results confirm the antiwrinkle activity of acetyl hexapeptide-3. A significant decrease in TEWL with acetyl hexapeptide-3 treatment is observed. We provided clinical evidence for the antiwrinkle efficacy of tripeptide-10 citrulline and possibly TEWL. The underlying mechanism by which these two peptides can act synergistically was not clear in this study.

BACKGROUND: Bioactive peptides have beneficial effects on the skin. OBJECTIVE: We investigated to evaluate the effect of acetyl hexapeptide-3 and tripeptide-10 citrulline and the possible synergism between these two peptides. METHODS: Twenty-four healthy volunteers were randomized to receive combination of acetyl hexapeptide-3 with tripeptide-10 citrulline (Group G1), tripeptide-10 citrulline (Group, G2), acetyl hexapeptide-3 (Group G3), or neither peptide (Group G4) for 60 days. Skin properties evaluated included skin microtopography, parameters cR2 and cR3, and transepidermal water loss (TEWL) using a skin visioscan and a tewameter, respectively. RESULTS: After 20 days, the measurements between G1 and G2 groups (cR2 P=.045, cR3 P=.044), G2 and G3 groups (cR2 P=.017, cR3 P=.017), G3 and G4 groups (CR2 P=.022), and G2 and G4 groups (cR3 P=.028) from baseline were significant. After 60 days, measurements between groups G1 and G3 (cR2 P=.016, cR3 P=.025), groups G2 and G3 (cR2 P=.044, cR3= P=.044), and groups G1 and G4 (cR2 P=.025) were significant. After 20 days, changes in TEWL between groups G1 and G3 (P=.03), groups G2 and G3 (P=.045), and groups G3 and G4 (P=.025) were significant. After 40 days, changes between groups G2 and G3 (P=.028) and groups G3 and G4 (P=.01) from baseline were significant. CONCLUSION: Our results confirm the antiwrinkle activity of acetyl hexapeptide-3. A significant decrease in TEWL with acetyl hexapeptide-3 treatment is observed. We provided clinical evidence for the antiwrinkle efficacy of tripeptide-10 citrulline and possibly TEWL. The underlying mechanism by which these two peptides can act synergistically was not clear in this study.